Exhibit 99.1

DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.	CONTACT
	INVESTOR RELATIONS	MEDIA RELATIONS
	KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297)	CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121)

Dr. Reddy’s Q3 and 9M FY16 Financial Results

Q3 Revenues at 39.7 billion (YoY growth of 3%) Q3 EBITDA at 10.1 billion (25.5% of the revenues) 9M Revenues at 117.1 billion (YoY growth of 7%) 9M EBITDA at 31.4 billion (26.8% of the revenues)

Hyderabad, India, February 9, 2016: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the quarter ended December 31, 2015 under International Financial Reporting Standards (IFRS).

Q3 FY16: Key Highlights

• Consolidated revenues at 39.7 billion, year-on-year growth of 3%. Growth is driven by healthy performance in NAG, Europe and India; partially offset by Emerging markets, which were impacted by unfavorable macro-economic conditions.

• Gross Profit Margin at 59.5%, improved by ~130 bps over last year

• Research & Development (R&D) spend at 4.1 billion. Continued focus on building complex generics and differentiated products pipeline.

• Selling, general & administrative (SG&A) expenses at 12.0 billion

• EBITDA at 10.1 billion, 25.5% of revenues.

• Profit after tax at 5.8 billion. Diluted EPS at 33.9

9M FY16: Key Highlights

• Consolidated revenues at 117.1 billion, year-on-year growth of 7%

• Gross Profit Margin at 60.6%, improved by ~200 bps over last year

• Research & Development (R&D) spend at 13.0 billion. Continued focus on building complex generics and differentiated products pipeline.

• Selling, general & administrative (SG&A) expenses at 34.1 billion

• EBITDA at 31.4 billion, 26.8% of revenues

• Profit after tax at 19.3 billion. Diluted EPS at 112.6

Commenting on the company’s third quarter results, Co-chairman and CEO, G V Prasad said “Despite multiple challenges we have had a satisfactory quarter in terms of our financial performance. All of our key markets continue to perform well and show healthy growth. However, our performance has been impacted due to adverse macro-economic conditions across key emerging market territories. The two approvals and one tentative approval of our NDAs in the very first review cycle has been a positive development and lays the foundation for building a strong and sustainable proprietary products business. Enhancing our quality management practices and meeting the US FDA expectations continues to be our highest priority.”

All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = 66.19

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement

Particulars	Q3 FY 16									Q3 FY 15									Growth %
	($)			(Rs.)			%			($)			(Rs.)			%
Revenues		599			39,679			100.0			581			38,431			100.0			3
Cost of revenues		243			16,089			40.5			243			16,079			41.8			0
Gross profit		356			23,590			59.5			338			22,352			58.2			6
Operating Expenses
Selling, general & administrative expenses		182			12,039			30.3			168			11,151			29.0			8
Research and development expenses		62			4,095			10.3			65			4,316			11.2			(5	)
Other operating expense / (income)		(2	)		(122	)		(0.3	)		(5	)		(341	)		(0.9	)		(64	)
Results from operating activities		114			7,578			19.1			109			7,226			18.8			5
Finance expense / (income), net		1			62			0.2			(15	)		(1,013	)		(2.6	)		NA
Share of profit of equity accounted investees, net of income tax		(1	)		(64	)		(0.2	)		(1	)		(47	)		(0.1	)		38
Profit before income tax		115			7,580			19.1			125			8,286			21.6			(9	)
Income tax expense		27			1,788			4.5			38			2,541			6.6			(30	)
Profit for the period		88			5,792			14.6			87			5,745			15.0			1
Diluted EPS		0.51			33.86						0.51			33.61						1

EBITDA Computation

Particulars	Q3 FY 16						Q3 FY 15
	($)			(Rs.)			($)			(Rs.)
Profit before tax		115			7,580			125			8,286
Interest (income) / expense net*		(4	)		(236	)		(5	)		(347	)
Depreciation		25			1,685			22			1,462
Amortization		13			892			9			579
Impairment		3			194			8			534
EBITDA		153			10,115			159			10,515
EBITDA (% to sales)					25.5						27.4

* Includes income from investments

All amounts in millions, except EPS All US dollar amounts based on convenience translation rate of I USD = 66.19

Key Balance Sheet Items

Particulars	As on 31st Dec 15				As on 30th Sep 15
	($)		(Rs.)		($)		(Rs.)
Cash and cash equivalents and Other current Investments		575		38,028		514		34,050
Trade receivables		633		41,904		647		42,840
Inventories		403		26,689		410		27,147
Property, plant and equipment		797		52,736		771		51,055
Goodwill and Other Intangible assets		374		24,739		365		24,155
Loans and borrowings (current & non-current)		511		33,801		560		37,072
Trade payables		179		11,833		193		12,766
Equity		1,944		128,681		1,836		121,499

Revenue Mix by Segment

Particulars	Q3 FY 16						Q3 FY 15						Growth %
	($)		(Rs.)		%		($)		(Rs.)		%
Global Generics		507		33,558		84		473		31,335		81		7
North America				19,417						16,462				18
Europe*				1,937						1,702				14
India				5,805						4,328				34
Emerging Markets#				6,399						8,843				(28	)
PSAI		77		5,082		13		92		6,112		16		(17	)
North America				1,037						894				16
Europe				1,951						2,639				(26	)
India				622						948				(34	)
Rest of World				1,472						1,631				(10	)
Proprietary Products & Others		16		1,039		3		15		984		3		6
Total		599		39,679		100		581		38,431		100		3

* Europe primarily includes Germany, UK and out licensing sales business

# Emerging Markets refers to Russia, other CIS countries, Romania and Rest of the World markets including Venezuela

Note: Effective Q1 FY 16, there was a change in the monitoring of performance of one product from Global Generics to Proprietary Products. Consequently, revenues and related costs of this product for the previous periods have been reclassified to conform to such change.

Segmental Analysis

Global Generics

Revenues from Global Generics segment for Q3 FY16 are at 33.6 billion, year-on-year growth of 7%, primarily driven by North America, Europe and India.

• Revenues from North America for Q3 FY16 at 19.4 billion, year-on-year growth of 18%. Growth primarily on account of sustained performance of the injectable franchise and market share gains in key molecules

Four new generics filings in the US during the quarter (3 ANDAs and 1 NDA). Cumulatively, 82 generic filings are pending for approval with the USFDA (79 ANDAs and 3 NDAs under 505(b)(2) route). Of these 79 ANDAs, 52 are Para IVs out of which we believe 18 have ‘First to File’ status.

• Revenues from Emerging Markets for Q3 FY16 at 6.4 billion, year-on-year decline of 28%.

• Revenues from Russia at 3.1 billion, year-on-year decline of 21% primarily on account of depreciation of rouble. In constant currency revenues grew by 5% year-on-year over a high base in previous year

• Revenues from other CIS countries and Romania market at 0.9 billion, year-on-year decline of 17%.

• Revenues from Rest of World (RoW) territories at 2.4 billion, year-on-year decline of 38% primarily on account of calibrated sales in Venezuela.

• Revenues from India for Q3 FY16 at 5.8 billion, year-on-year growth of 34%.

• Continued momentum of mega brands.

• Portfolio acquired from UCB well-integrated into our supply chain

Normalizing for contribution from the UCB portfolio, growth of the base business during the quarter is healthy and in line with expectations

• Revenues from Europe for Q3 FY16 at 1.9 billion, year-on-year growth of 14%. Growth was primarily driven by aripiprazole and pregabalin.

Pharmaceutical Services and Active Ingredients (PSAI)

• Revenues from PSAI at 5.1 billion, and declined by 17% year-on-year.

• During the quarter, 21 DMFs were filed globally and 3 in the US. The cumulative number of DMF filings as of December 31, 2015 was 774.

Income Statement Highlights:

• Gross profit margin at 59.5% and improved by ~130 bps over that of previous year. Gross profit margin for Global Generics (GG) and PSAI business segments are at 65.6% and 17.4% respectively.

• SG&A expenses at 12.0 billion, year-on-year growth of 8%. This increase is largely due to the ongoing remediation activities related to the USFDA’s observations and Warning Letter, settlement of ongoing patent litigation with Novartis on zoledronic acid and certain routine items related to manpower and other spends.

• Research & development expenses at 4.1 billion, year-on-year decline of 5%. As a % to sales R&D expenses stood at 10.3% in Q3 FY16 as compared to 11.2% in Q3 FY15. The decline is largely due to the receipt of our share of development costs and other contractual amounts from Merck Serono for biosimilars development program.

• Net Finance expense at 62 million compared to the net finance income of 1,013 million in Q3 FY15. The incremental charge of 1,075 million is on account of:

• Net foreign exchange gain of 339 million in the current quarter vs net foreign exchange gain of 666 million in the previous year

• Certain monetary assets and liabilities of the Venezuelan subsidiary that may not qualify for translation at the CENCOEX rate of VEF 6.3 per USD, have been translated at the SIMADI rate of VEF 198.5 per USD and the resultant charge of 637 million has been recorded as foreign exchange loss.

• Decline in profit on sales of investments by 139 million.

• Net increase in interest income of 29 million.

• Profit after Tax at 5.8 billion, 14.6% of revenues, year-on-year growth of 1%.

• Diluted earnings per share is at 33.9

• Capital expenditure is at 3.1 billion.

Earnings Call Details (06.30 pm IST, February 9, 2016)

The Company will host an earnings call at 06.30 pm IST on February 9, 2016, to discuss the performance and answer any questions from participants. This call will be accessible through an audio dial-in and a web-cast.

Audio conference Participants can dial-in on the numbers below

Primary number:		91 22 3960 0616
Secondary number:		91 22 6746 5826
International Toll Free Number	USA	18667462133
	UK	08081011573
	Singapore	8001012045
	Hong Kong	800964448

Playback of call:	91 22 3065 2322, 91 22 6181 3322
Conference ID:	375#
Web-cast	More details will be provided through our website,
www.drreddys.com

Transcript of the event will be available at www.drreddys.com. Playback will be available for a few days.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS, Venezuela and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.

The company assumes no obligation to update any information contained herein.